Lexicon Pharmaceuticals
LXRX
127 hedge funds and large institutions have $122M invested in Lexicon Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 31 funds opening new positions, 34 increasing their positions, 32 reducing their positions, and 30 closing their positions.
588% more call options, than puts
Call options by funds: $358K | Put options by funds: $52K
6% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 32
3% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 30
0% more funds holding
Funds holding: 127 → 127 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
8.82% less ownership
Funds ownership: 82.35% → 73.52% (-8.8%)
44% less capital invested
Capital invested by funds: $220M → $122M (-$97.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIBC Private Wealth Group
Atlanta,
Georgia
|
+$1.41M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$889K |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$740K |
| 4 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$509K |
| 5 |
MAM
Monaco Asset Management
Monaco
|
+$463K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$11M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.64M |
| 3 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$3.88M |
| 4 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$1.76M |
| 5 |
PA
Pinnacle Associates
New York
|
-$865K |
LXRX Hedge Fund Activity: Q1 2025 in Review
127 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Lexicon Pharmaceuticals (LXRX) for Q1 2025, worth a combined $122M — down 44% from $220M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new LXRX positions and 30 closed out — a net gain of 1 holder — while 34 added to existing stakes and 32 trimmed.
The largest buyer was CIBC Private Wealth Group, opening a new position worth an estimated $1.41M. The largest seller was Fidelity Investments, cutting an estimated $11M.
- 127 institutional investors held Lexicon Pharmaceuticals (LXRX) as of Q1 2025, unchanged from Q4 2024.
- Funds reported $122M of Lexicon Pharmaceuticals stock for Q1 2025, down 44% quarter-over-quarter.
- 31 funds opened new Lexicon Pharmaceuticals positions in Q1 2025 and 30 closed out, a net change of +1 holder.
- The largest Lexicon Pharmaceuticals buyer in Q1 2025 was CIBC Private Wealth Group, an estimated $1.41M added.
- The largest Lexicon Pharmaceuticals seller in Q1 2025 was Fidelity Investments, an estimated $11M sold.
Based on aggregated 13F filings for Q1 2025.